mAbs in nonlupus autoimmune rheumatic disease

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Monoclonal antibody (mAb) therapies are increasingly utilized across various medical fields.
• Their application in rare autoimmune rheumatic diseases, including autoimmune myositis, vasculitis, and primary Sjogren's syndrome, is growing.
• The use of these advanced therapies in rare diseases often outpaces robust clinical trial data.

Purpose of the Study:

• To review and summarize existing evidence supporting the use of mAb therapies in autoimmune myositis, vasculitis, and primary Sjogren's syndrome.
• To evaluate the efficacy and safety of mAb treatments in these specific rare rheumatic conditions.
• To assess the current evidence base for mAb therapies in the context of autoimmune rheumatic diseases.

Main Methods:

• Systematic review of available literature, including open-label trials and case reports.
• Focus on specific mAb agents such as rituximab and anti-tumour necrosis factor-alpha (anti-TNFα) agents.
• Analysis of treatment outcomes for autoimmune myositis, vasculitis, and primary Sjogren's syndrome.

Main Results:

• Open-label trials and case reports indicate general efficacy for mAb therapies, primarily rituximab and anti-TNFα agents.
• A notable exception was the inefficacy observed with anti-TNFα agents combined with cyclophosphamide for vasculitis treatment.
• mAb therapies have demonstrated effectiveness in patients who have not responded to traditional treatments.

Conclusions:

• Monoclonal antibody therapies are effective for autoimmune rheumatic diseases in patients refractory to conventional treatments.
• Current evidence does not support the routine use of mAb therapies as a first-line treatment over established immunosuppressive strategies.
• Further large-scale randomized controlled trials are needed to solidify the role of mAbs in these rare conditions.